Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Xu, Zhi ^a   Huo, Xinying ^a   Ye, Hua ^b   Tang, Chuanning ^b   Nandakumar, Vijayalakshmi ^c   Lou, Feng ^b   Zhang, Dandan ^b   Dong, Haichao ^b   Sun, Hong ^b   Jiang, Shouwen ^b   Zhang, Guangchun ^b   Liu, Zhiyuan ^b   Dong, Zhishou ^b   Guo, Baishuai ^b   He, Yan ^b   Yan, Chaowei ^b   Wang, Lu ^b   Su, Ziyi ^b   Li, Yangyang ^b   Gu, Dongying ^a   Zhang, Xiaojing ^a   Wu, Xiaomin ^a   Wei, Xiaowei ^a   Hong, Lingzhi ^a   Zhang, Yangmei ^a   Yang, Jinsong ^a   Gong, Yonglin ^a   Tang, Cuiju ^a   Jones, Lindsey ^c   Huang, Xue F ^c   Chen, Si Yi ^c   Chen, Jinfei ^a   more..

^a NANJING MEDICAL UNIVERSITY   (China)

^b San Valley Biotechnology Incorporated   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER TISSUE; DNA SEQUENCE; EXON; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; ION TORRENT SEQUENCING PLATFORM; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONCOGENE; SOMATIC MUTATION; STOMACH ADENOCARCINOMA; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC LOCI; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; MUTATION, MISSENSE; NEOPLASM GRADING; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904252814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100442     Document Type: Article

References (44)

1. Davis PA, Sano T (2001) The difference in gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions? Critical reviews in oncology/hematology 40: 77-94. (Pubitemid 32918199)
2. Borch K, Jönsson B, Tarpila E, Franzén T, Berglund J, et al. (2000) Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. British Journal of Surgery 87: 618-626. (Pubitemid 30261099)
3. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJH (2002) Value of palliative resection in gastric cancer. British Journal of Surgery 89: 1438-1443.
4. Okines AFC, Cunningham D (2010) Trastuzumab in gastric cancer. European journal of cancer (Oxford, England: 1990) 46: 1949-1959.
5. Arkenau H-T (2009) Gastric cancer in the era of molecularly targeted agents: current drug development strategies. Journal of Cancer Research and Clinical Oncology 135: 855-866.
6. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochemical and Biophysical Research Communications 189: 227-232. (Pubitemid 23030031)
7. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, et al. (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clinical Cancer Research 2: 1373-1381. (Pubitemid 26299437)
8. Khosravi Shahi P, Díaz Muñoz de la Espada VM, García Alfonso P, Encina García S, Izarzugaza Perón Y, et al. (2007) Management of gastric adenocarcinoma. Clinical and Translational Oncology 9: 438-442.
9. Metzker ML (2010) Sequencing technologies [mdash] the next generation. Nat Rev Genet 11: 31-46.
10. Suzuki S, Ono N, Furusawa C, Ying B-W, Yomo T (2011) Comparison of Sequence Reads Obtained from Three Next-Generation Sequencing Platforms. PLoS ONE 6: e19534.
11. Pourmand N, Karhanek M, Persson HHJ, Webb CD, Lee TH, et al. (2006) Direct electrical detection of DNA synthesis. Proceedings of the National Academy of Sciences 103: 6466-6470.
12. (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073.
13. (March 19, 2013 accessed) Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. http://evsgswashingtonedu/EVS/.
14. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British journal of cancer 91: 355-358. (Pubitemid 39037083)
15. Sigal A, Rotter V (2000) Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome. Cancer Research 60: 6788-6793. (Pubitemid 32059139)
16. Pfeifer G, Besaratinia A (2009) Mutational spectra of human cancer. Human Genetics 125: 493-506.
17. Ory K LY, Auguin C, Soussi T. (1994 Aug 1) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504. (Pubitemid 24246186)
18. Peart MJ, Prives C (2006) Mutant p53 gain of function: the NF-Y connection. Cancer Cell 10: 173-174. (Pubitemid 44311071)
19. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165. (Pubitemid 46536647)
20. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, et al. (1991) Helicobacter pylori Infection and the Risk of Gastric Carcinoma. New England Journal of Medicine 325: 1127-1131.
21. Machado AMD, Figueiredo C, Seruca R, Rasmussen LJ (2010) Helicobacter pylori infection generates genetic instability in gastric cells. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806: 58-65.
22. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219-1223.
23. Holbrook J, Parker J, Gallagher K, Halsey W, Hughes A, et al. (2011) Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. Journal of Translational Medicine 9: 119.
24. Nagarajan N, Bertrand D, Hillmer A, Zang Z, Yao F, et al. (2012) Wholegenome reconstruction and mutational signatures in gastric cancer. Genome Biology 13: R115.
25. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
26. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, et al. (2011) Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 35: 625-632.
27. Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542.
28. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, et al. (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
29. Deng N, Goh LK, Wang H, Das K, Tao J, et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684.
30. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, et al. (2011) Oncogenic mutations in gastric cancer with microsatellite instability. European Journal of Cancer 47: 443-451.
31. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376: 687-697.
32. Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, et al. (2011) A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117: 1409-1414.
33. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, et al. (2006) Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients. Journal of Clinical Oncology 24: 1612-1619. (Pubitemid 46638785)
34. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, et al. (2007) A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response. Clinical Cancer Research 13: 5869-5875. (Pubitemid 47583913)
35. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, et al. (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Annals of Oncology 22: 1367-1373.
36. Vidal Ó, Metges JP, Elizalde I, Valentíni M, Volant A, et al. (2009) High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. British Journal of Surgery 96: 1443-1451.
37. Chen J, Li T, Wu Y, He L, Zhang L, et al. (2011) Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a metaanalysis. Journal of Cancer Research and Clinical Oncology 137: 1799-1812.
38. Al-Batran S-E, Ducreux M, Ohtsu A (2012) mTOR as a therapeutic target in patients with gastric cancer. International Journal of Cancer 130: 491-496.
39. Doi T, Muro K, Boku N, Yamada Y, Nishina T, et al. (2010) Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer. Journal of Clinical Oncology 28: 1904-1910.
40. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, et al. (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106: 1039-1044.
41. Chen C-T, Kim H, Liska D, Gao S, Christensen JG, et al. (2012) MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells. Molecular Cancer Therapeutics 11: 660-669.
42. Catenacci DVT, Henderson L, Xiao S-Y, Patel P, Yauch RL, et al. (2011) Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery 1: 573-579.
43. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, et al. (2000) An Indolocarbazole Inhibitor of Human Checkpoint Kinase (Chk1) Abrogates Cell Cycle Arrest Caused by DNA Damage. Cancer Research 60: 566-572. (Pubitemid 30094552)
44. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, et al. (2000) The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01. Journal of Biological Chemistry 275: 5600-5605. (Pubitemid 30115197)